JUNS Stock Sees Best Single-Day Gains In Almost A Year On $100M MDMA Drug Licensing Deal  – Retail Expects Shares To Hit $1

• The agreement carries a potential value of up to $100 million, but Jupiter will make an upfront payment of $3.3 million.
• ALA-002 is a patented MDMA formulation recognized by the U.S. Food and Drug Administration as a novel chemical entity.
• JUNS stock is set to test a key technical milestone for the first time in nearly seven months.

Shares of Jupiter Neurosciences, Inc. (JUNS) surged more than 50% in early trade on Wednesday, clocking its biggest single-day gains in nearly a year, after it signed a term sheet to acquire exclusive U.S. licensing rights to an MDMA-based drug candidate developed by PharmAla Biotech.

JUNS stock is also set to test its 100-day moving average (100-DMA) for the first time since October 2025.

Source: TradingView

JUNS To Pay $3.3M Upfront

As part of the $100 million term sheet, Jupiter will pay $3.33 million upfront, including $1.5 million in cash and $1.83 million in company stock. The deal also includes future milestone payments and royalties tied to the development and commercialization of the therapy.

ALA-002 is a patented MDMA formulation recognized by the U.S. Food and Drug Administration (FDA) as a novel chemical entity. The therapy is designed to improve cardiovascular safety and reduce abuse risks while maintaining the therapeutic effects linked to MDMA-assisted treatment.

“ALA-002 represents the type of innovative, next-generation asset we believe can play a pivotal role in future neuropsychiatric therapies,” said Alison Silva, President and Chief Business Officer of Jupiter Neurosciences.

Psychedelic Market Sees Regulatory Traction

The announcement comes after President Donald Trump signed an executive order in April aimed at accelerating access to psychedelic treatments for serious mental illnesses such as PTSD. The order directs the regulatory bodies like the FDA and Drug Enforcement Administration (DEA) to expand pathways for investigational psychedelic therapies and increase federal support for related research programs.

Jupiter said the deal positions the company to benefit from the fast-growing psychedelic therapeutics market, which is expected to become a multi-billion-dollar industry in the United States.

JUNS Bulls Eye $1

Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.

One user saw a strong buying opportunity at current levels, adding that there is a “green light going forward.”

Another user said the stock could climb to $1.

JUNS shares have tanked around 60% so far this year.

Read also: ROIV Stock Nears Record High: Moderna Settlement Drives Q4 Profit, But Pipeline Catalysts Keep Retail Interested

For updates and corrections, email newsroom[at]stocktwits[dot]com.